Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven

Molecular Cancer Therapeutics

Volumn 5, Issue 12, 2006, Pages 3153-3161

  Wang, Yutian ^a   Wiltshire, Timothy ^a   Senft, Jamie ^a   Wenger, Sharon L ^a   Reed, Eddie ^a,b   Wang, Weixin ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; ATM PROTEIN; ATR PROTEIN; DOUBLE STRANDED DNA; FANCONI ANEMIA GROUP D2 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CHROMOSOME ABERRATION; CHROMOSOME STRUCTURE; CONTROLLED STUDY; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; UBIQUITINATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHROMOSOMES, HUMAN; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; OVARIAN NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SESQUITERPENES; TRANSFECTION; UBIQUITINS;

EID: 33846211831     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0427     Document Type: Article

References (59)

1. Venkitaraman AR. Tracing the network connecting BRCA and Fanconi anaemia proteins. Nat Rev Cancer 2004;4:266-76.
2. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003;3:23-34.
3. Timmers C, Taniguchi T, Hejna J, et al. Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol Cell 2001;7:241-8.
4. Garcia-Higuera I, Taniguchi T, Ganesan S, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001;7:249-62.
5. Meetei AR, Yen Z, Wang W. FANCL replaces BRCA1 as the likely ubiquitin ligase responsible for FANCD2 monoubiquitination. Cell Cycle 2004;3:179-81.
6. Thompson LH. Unraveling the Fanconi anemia-DNA repair connection. Nat Genet 2005;37:921-2.
7. Mosedale G, Niedzwiedz W, Alpi A, et al. The vertebrate Hef ortholog is a component of the Fanconi anemia tumor-suppressor pathway. Nat Struct Mol Biol 2005;12:763-71.
8. Litman R, Peng M, Jin Z, et al. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 2005;8:255-65.
9. Medhurst AL, Huber PA, Waisfisz Q, de Winter JP, Mathew CG. Direct interactions of the five known Fanconi anaemia proteins suggest a common functional pathway. Hum Mol Genet 2001;10:423-9.
10. Meetei AR, Sechi S, Wallisch M, et al. A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome. Mol Cell Biol 2003;23: 3417-26.
11. Meetei AR, de Winter JP, Medhurst AL, et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet 2003;35:165-70.
12. Meetei AR, Levitus M, Xue Y, et al. X-linked inheritance of Fanconi anemia complementation group B. Nat Genet 2004;36:1219-24.
13. Meetei AR, Medhurst AL, Ling C, et al. A human orthologi of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. Nat Genet 2005;37:958-63.
14. Nijman SM, Huang TT, Dirac AM, et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell 2005;17:331-9.
15. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002;297:606-9.
16. Wang X, Andreassen PR, D'Andrea AD. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol Cell Biol 2004;24:5850-62.
17. Hussain S, Wilson JB, Medhurst AL, et al. Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. Hum Mol Genet 2004;13:1241-8.
18. Vandenberg CJ, Gergely F, Ong CY, et al. BRCA1-independent ubiquitination of FANCD2. Mol Cell 2003;12:247-54.
19. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-9.
20. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004;4:665-76.
21. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-82.
22. van der Heijden MS, Yeo CJ, Hruban RH, Kern SE. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003;63: 2585-8.
23. Rogers CD, Van Der Heijden MS, Brune K, et al. The Genetics of FANCC and FANCG in Familial Pancreatic Cancer. Cancer Biol Ther 2004; 3:167-9.
24. Martin ST, Matsubayashi H, Rogers CD, et al. Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene 2005;24:3652-6.
25. Rogers CD, Couch FJ, Brune K, et al. Genetics of the FANCA gene in familial pancreatic cancer. J Med Genet 2004;41:e126.
26. Goggins M, Hruban RH, Kern SE. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol 2000;156:1767-71.
27. Arnold MA, Goggins M. BRCA2 and predisposition to pancreatic and other cancers. Expert Rev Mol Med 2001;2001:1-10.
28. Hughes-Davies L, Huntsman D, Ruas M, et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003;115:523-35.
29. Narayan G, Arias-Pulido H, Nandula SV, et al. Promoter hypermethylation of FANCF: disruption of Fanconi anemia-BRCA pathway in cervical cancer. Cancer Res 2004;64:2994-7.
30. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 2004;23: 1000-4.
31. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003;9:568-74.
32. MacDonald JR, Muscoplat CC, Dexter DL, et al. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res 1997;57:279-83.
33. Sato Y, Kashimoto S, MacDonald JR, Nakano K. In vivo antitumour efficacy of MGI-114 (6-hydroxymethylacylfulvene, HMAF) in various human tumour xenograft models including several lung and gastric tumours. Eur J Cancer 2001;37:1419-28.
34. Friedman HS, Keir ST, Houghton PJ, Lawless AA, Bigner DD, Waters SJ. Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice. Cancer Chemother Pharmacol 2001;48:413-6.
35. Hidalgo M, Izbicka E, Eckhardt SG, et al. Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units. Anticancer Drugs 1999;10:837-44.
36. Britten CD, Hilsenbeck SG, Eckhardt SG, et al. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer Res 1999;59:1049-53.
37. Murgo A, Cannon DJ, Blatner G, Cheson BD. Clinical trials referral resource. Clinical trials of MGI-114. Oncology (Williston Park) 1999;13: 233, 237-8.
38. Kelner MJ, McMorris TC, Rojas RJ, et al. Enhanced antitumor activity of irofulven in combination with antimitotic agents. Invest New Drugs 2002;20:271-9.
39. Senzer N, Arsenau J, Richards D, Berman B, MacDonald JR, Smith S. Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial. Am J Clin Oncol 2005;28:36-42.
40. Woo MH, Peterson JK, Billups C, Liang H, Bjornsti MA, Houghton PJ. Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models. Cancer Chemother Pharmacol 2005;55:411-9.
41. Kelner MJ, McMorris TC, Estes L, et al. Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells. Unusually high sensitivity of ERCC2 and ERCC3 DNA helicase-deficient mutants in comparison to other chemotherapeutic agents. Biochem Pharmacol 1994;48:403-9.
42. Kelner MJ, McMorris TC, Estes L, et al. Efficacy of Acylfulvene Illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells. Cancer Res 1995; 55:4936-40.
43. Jaspers NG, Raams A, Kelner MJ, et al. Anti-tumour compounds illudin S and Irofulven induce DNA lesions ignored by global repair and exclusively processed by transcription- and replication-coupled repair pathways. DNA Repair (Amst) 2002;1:1027-38.
44. Wang J, Wiltshire T, Wang Y, et al. ATM-dependent CHK2 activation induced by anticancer agent, irofulven. J Biol Chem 2004; 279:39584-92.
45. Ismail IH, Nystrom S, Nygren J, Hammarsten O. Activation of ataxia telangiectasia mutated by DNA strand break-inducing agents correlates closely with the number of DNA double strand breaks. J Biol Chem 2005; 280:4649-55.
46. Buscemi G, Perego P, Carenini N, et al. Activation of ATM and Chk2 kinases in relation to the amount of DNA strand breaks. Oncogene 2004; 23:7691-700.
47. Ziv Y, Bar-Shira A, Pecker I, et al. Recombinant ATM protein complements the cellular A-T phenotype. Oncogene 1997;15:159-67.
48. Cliby WA, Roberts CJ, Cimprich KA, et al. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J 1998;17:159-69.
49. Casper AM, Nghiem P, Arlt MF, Glover TW. ATR regulates fragile site stability. Cell 2002;111:779-89.
50. Taniguchi T, Garcia-Higuera I, Andreassen PR, Gregory RC, Grompe M, D'Andrea AD. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 2002;100: 2414-20.
51. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998;58:1120-3.
52. Taniguchi T, Garcia-Higuera I, Xu B, et al. Convergence of the Fanconi anemia and ataxia telangiectasia signaling pathways. Cell 2002;109: 459-72.
53. Pichierri P, Rosselli F. The DNA crosslink-induced S-phase checkpoint depends on ATR-CHK1 and ATR-NBS1-2 pathways. EMBO J 2004;23: 1178-87.
54. Andreassen PR, D'Andrea AD, Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev 2004;18: 1958-63.
55. Nakanishi K, Yang YG, Pierce AJ, et al. Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc Natl Acad Sci U S A 2005;102:1110-5.
56. Park WH, Margossian S, Horwitz AA, Simons AM, D'Andrea AD, Parvin JD. Direct DNA binding activity of the Fanconi anemia D2 protein. J Biol Chem 2005;280:23593-8.
57. Howlett NG, Taniguchi T, Durkin SG, D'Andrea AD, Glover TW. The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability. Hum Mol Genet 2005;14:693-701.
58. Rothfuss A, Grompe M. Repair kinetics of genomic interstrand DNA cross-links: evidence for DNA double-strand break-dependent activation of the Fanconi anemia/BRCA pathway. Mol Cell Biol 2004; 24:123-34.
59. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003;3:155-68.